Trillium Therapeutics Inc is a biopharmaceutical organization developing therapies for cancer treatment.
The immuno-oncology company is working on two programs, TTI-621 and TTI-622, a protein fusion that targets the CD47 and functions as a 'don’t eat me' signal, allowing cancer cell to evade the immune system.
CD47, an immune checkpoint, delivers signals to macrophages and inhibits phagocytosis.
The small molecule of receptors increases the patient’s immune system's ability to detect and destroys cancer cells, reportedly.
The Ontario-based firm, founded in 2004, is named the official flower of the province, Trillium Grandiflorum. Until 2014, it was known as Stem Cell Therapeutics Corp.
As a leading cancer treatment company, it is focused on hematological malignancies that are being evaluated in patients.
Under the new leadership program at the end of 2019, Trillium underwent a corporate reorganization, which established it as a clinical development-centric organization focusing on hematology and oncology indications.
Its offices are located in Mississauga, Cambridge, Ontario, and the United States.
Trillium provides treatment solutions for patients fighting cancer.
The company claims that high CD47 correlates with poorer clinical outcomes and more aggressive disease. In addition, it claims that interrupting the signal pathway of CD47-SIRPα has shown both in vivo and in vitro anti-tumor activity against human cancers in preclinical studies.
As an emerging therapeutic strategy, blocking CD47 enhances anti-tumor activity in patients and provides benefit to the patients, the biopharmaceutical company claims.
The Ontario-based business is developing two decoy receptors that prevent tumor cells from evading the patient’s immune systems and promotes destruction.
Two decoy receptors being developed by the firm blocks the CD47 inhibit signal’s negative response and delivers a positive activating signal in the fragment crystallizable region or Fc gamma receptors, thereby increasing macrophages’ ability to destroy cancer cells.
TTI-622 is a dual molecule that prevents CD47 binding on cancer cells and sends positive signals to the patient’s immune system.
Studies represent that SIRPαFc fusion proteins, IgG4 have lower potency than IgG1 fusion proteins, but it consists of higher tolerability, the company claims.
TTI-622 is also a SIRPαFc immune checkpoint that inhibits CD47 to the same degree a modest activating signal, allowing for a higher dosage, the biopharmaceutical company claims.
The decoy receptors are presently being evaluated in individuals detected with hematological malignancies and solid tumors.